Paramyotonia Congenita
Symptoms, Doctors, Treatments, Advances & More

Learn About Paramyotonia Congenita

What is the definition of Paramyotonia Congenita?

Paramyotonia congenita is a disorder that affects muscles used for movement (skeletal muscles). Beginning in infancy or early childhood, people with this condition experience bouts of sustained muscle tensing (myotonia) that prevent muscles from relaxing normally. Myotonia causes muscle stiffness that typically appears after exercise and can be induced by muscle cooling. This stiffness chiefly affects muscles in the face, neck, arms, and hands, although it can also affect muscles used for breathing and muscles in the lower body. Unlike many other forms of myotonia, the muscle stiffness associated with paramyotonia congenita tends to worsen with repeated movements.

What are the causes of Paramyotonia Congenita?

Mutations in the SCN4A gene cause paramyotonia congenita. This gene provides instructions for making a protein that is critical for the normal function of skeletal muscle cells. For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by the flow of positively charged atoms (ions), including sodium, into skeletal muscle cells. The SCN4A protein forms channels that control the flow of sodium ions into these cells.

How prevalent is Paramyotonia Congenita?

Paramyotonia congenita is an uncommon disorder; it is estimated to affect fewer than 1 in 100,000 people.

Is Paramyotonia Congenita an inherited disorder?

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In many cases, an affected person has one parent with the condition.

Who are the top Paramyotonia Congenita Local Doctors?
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita

Office

355 W 16th St Ste 3200, 
Indianapolis, IN 
Languages Spoken:
English

Laurie Gutmann is a Neurologist in Indianapolis, Indiana. Dr. Gutmann is rated as an Elite provider by MediFind in the treatment of Paramyotonia Congenita. Her top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy Type 2, Myotonic Dystrophy, and Charcot-Marie-Tooth Disease.

Jeffrey M. Statland
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
Experience:
21+ years
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Jeffrey Statland is a Neurologist in Fairway, Kansas. Dr. Statland has been practicing medicine for over 21 years and is rated as an Elite provider by MediFind in the treatment of Paramyotonia Congenita. His top areas of expertise are Facioscapulohumeral Muscular Dystrophy (FSHD), Paramyotonia Congenita, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Gastrostomy. Dr. Statland is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita

Office

1001 E Leigh St Fl 13, 
Richmond, VA 
Languages Spoken:
English
Offers Telehealth

Nicholas Johnson is a Neurologist in Richmond, Virginia. Dr. Johnson is rated as an Elite provider by MediFind in the treatment of Paramyotonia Congenita. His top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy Type 2, Myotonic Dystrophy, and Limb-Girdle Muscular Dystrophy.

What are the latest Paramyotonia Congenita Clinical Trials?
A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1

Summary: The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)

Summary: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)

Who are the sources who wrote this article ?

Published Date: August 01, 2015
Published By: National Institutes of Health